Group | Â | Number of patients | Age in years | Duration | Female/Male | RF | CCP | CRP | ESR |
---|---|---|---|---|---|---|---|---|---|
A |  | 14 | 56.1 ± 10.8a | 12.2 ± 9.2 | 12/2 | 89.6 ± 116.7 | 63.3 ± 66.9c | 1.55 ± 1.86 | 33.2 ± 16.8 |
B |  | 5 | 66.6 ± 2.1a | 11.4 ± 5.4 | 4/1 | 422.6 ± 574.5 | 385.6 ± 396.1 | 0.88 ± 0.79 | 41.8 ± 23.4 |
C |  | 6 | 65.7 ± 7.8 | 17.2 ± 12.7 | 6/0 | 139.3 ± 146.2 | 63.8 ± 55.5d | 0.97 ± 0.95 | 38.3 ± 27.9 |
D |  | 5 | 61.2 ± 21.0 | 6.3 ± 5.8 | 4/1 | 47.5 ± 47.0 | 164.0 ± 84.9c, d | 1.18 ± 1.48 | 31.0 ± 19.1 |
Anti-citrullinated CapZα-1 | +(B+C+D) | 16 | 64.6 ± 12.0 | 11.6 ± 9.2 | 14/2 | 199.2 ± 348.5 | 195.7 ± 253.2 | 1.01 ± 1.03 | 37.1 ± 22.9 |
 | -(A) | 14 | 56.1 ± 10.8 | 12.2 ± 9.2 | 12/2 | 89.6 ± 116.7 | 63.3 ± 66.9 | 1.55 ± 1.86 | 33.2 ± 16.8 |
Citrulline-unrelated epitope | + (C+D) | 11 | 63.6 ± 14.6 | 11.7 ± 10.9 | 10/1 | 97.6 ± 117.8 | 109.3 ± 84.7 | 1.06 ± 1.16 | 35.0 ± 23.4 |
 | -(A+B) | 19 | 58.8 ± 10.4 | 12.0 ± 8.2 | 16/3 | 177.3 ± 325.4 | 148.1 ± 243.7 | 1.37 ± 1.65 | 35.5 ± 18.5 |
Citrulline-related epitope | + (B+C) | 11 | 66.1 ± 5.7b | 14.3 ± 9.7 | 10/1 | 268.1 ± 405.7 | 210.1 ± 304.2 | 0.93 ± 0.84 | 39.9 ± 24.7 |
 | -(A+D) | 19 | 57.4 ± 13.7b | 10.7 ± 8.7 | 16/3 | 78.6 ± 103.4 | 89.8 ± 83.2 | 1.45 ± 1.74 | 32.6 ± 16.9 |